CenterBook Partners LP Acquires Shares of 30,104 Jazz Pharmaceuticals PLC $JAZZ

CenterBook Partners LP acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 30,104 shares of the specialty pharmaceutical company’s stock, valued at approximately $5,118,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JAZZ. Hilltop National Bank acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $36,000. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at about $38,000. Danske Bank A S acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at about $40,000. Geneos Wealth Management Inc. increased its position in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of several research reports. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Morgan Stanley reaffirmed an “overweight” rating and issued a $245.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Sanford C. Bernstein began coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, May 21st. They issued a “market perform” rating and a $229.00 target price on the stock. Wells Fargo & Company raised their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Bank of America raised their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $242.65.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the sale, the director owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. This trade represents a 22.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the sale, the director directly owned 18,449 shares in the company, valued at $4,446,209. The trade was a 9.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 10,741 shares of company stock worth $2,287,143 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $238.57 on Monday. The company has a market capitalization of $14.97 billion, a price-to-earnings ratio of -11,922.54, a P/E/G ratio of 0.22 and a beta of 0.32. The firm’s 50 day simple moving average is $213.11 and its 200 day simple moving average is $187.01. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.